3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
5
Neoplasm Metastasis
3
Carcinoma, Merkel Cell
3
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
3
pembrolizumab
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Biopsy
2
talimogene laherparepvec
1
peposertib
1
liposomal doxorubicin
1
fludarabine
1
aldesleukin
1
X-Rays
1
Radiotherapy
1
Radiation
1
Nivolumab
1
Ipilimumab
1
Histamine H2 Antagonists
1
Famotidine
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
avelumab
×
30 days
×
Clear all
No trials found.